NCT04681833View on ClinicalTrials.gov

Safety and Efficacy of BARS13 in the Elderly

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

January 26, 2024

Study Completion Date

April 2, 2024

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

Recombinant Respiratory Syncytial Virus Vaccine (BARS13) /placebo

Low Repeat Dose

DRUG

Recombinant Respiratory Syncytial Virus Vaccine (BARS13)

High Repeat Dose/High Repeat Multiple Dose

DRUG

Placebo

Liquid diluent/Lyophilised Powder

Trial Locations (2)

4006

Q-Pharm Pty Ltd, Herston

Unknown

CMAX Clinical Research, Adelaide

All Listed Sponsors
lead

Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

INDUSTRY